Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.
Position Overview
We are seeking a highly motivated and experienced Manager of CMC Stability Management and Analysis to join our team. This individual will lead the implementation and management of small molecule CMC stability programs at Immunome, for varegacestat, our lead compound nearing NDA submission. This individual will also perform statistical analysis, trending analysis as well as managing stability database. The incumbent will interpret and present stability data to all stake holder on a routine basis.
Responsibilities
- Lead the Stability database strategic and operational planning.
- Collaborate with analytical laboratories managing all stability studies.
- Manage the implementation, monitoring, maintenance and upgrade of the stability database.
- Maintain a data collection plan and statistical methods to evaluate stability, product performance, shelf-life projections and trend analysis.
- Maintain a Database that supports the entire life-cycle of a product from development to commercialization.
- Perform statistical analysis of stability data to support effective, well-informed, data-driven decision making.
- Interpret and present stability data to team leaders, regulatory bodies and other stakeholders in a comprehensive format as required.
- Manage reference standard and reference material program(s)
- Write and/or review stability reports and technical development reports
- Manage, conduct or support investigations, change controls and CAPAs related to stability samples.
- Prepare and assist in the preparation of regulatory submissions.
Qualifications
- BS in Analytical Chemistry or related discipline with a minimum of 5+ years’ experience in pharmaceutical/ biotechnology industry or MS with 3+ years of experience in the pharmaceutical/ biotechnology industry.
- A minimum of 2 years of experience managing stability programs, preferably including late stage clinical/commercial programs.
- Experience working with and managing third party vendors for stability programs.
Knowledge and Skills
- Experience in Database and Information Management, SlimStat, Statistical Analysis and Reporting, and Analytical Method Development and Control.
- Thorough knowledge of GLPs and GMPs as they relate to stability management.
- Expertise with statistical analysis software, interpretation of analytical data, ability to draw conclusions and strong understanding of current analytical methodologies.
- Able to present data to stakeholders or decision makers in the most informative/effective format.
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).
Top Skills
What We Do
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
